An antibody targeting only CD146 expressed in tumor cells has already been tested in preclinical studies, demonstrating its effectiveness in reducing proliferation, migration, and tube formation in vitro and tumor growth and metastasis formation in vivo [4,5,6,7,8]. This evidence concerns the gene MCAM and neoplasm.